Mayo Clinic | Strategic Alliance Partners

Radiopharmaceuticals have been integrated into the treatment paradigm for patients with neuroendocrine tumors, yet there are nuances in the clinical scenarios in which they are most effective.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the tolerability of encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated metastatic colorectal cancer.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the impact of the BEACON CRC trial in patients with BRAF V600E-mutated metastatic colorectal cancer.

Amit Mahipal, MBBS, senior associate consultant, Division of Medical Oncology, Department of Oncology, associate professor of oncology, Mayo Clinic, discusses emerging molecular markers in patients with metastatic colorectal cancer (mCRC).

Aaron S. Mansfield, MD, associate professor of oncology, consultant in the Division of Medical Oncology, Mayo Clinic, discusses the current treatment paradigm for patients with extensive-stage small cell lung cancer (SCLC) and highlights ongoing research in the field.

Aaron S. Mansfield, MD, associate professor of oncology, consultant in the Division of Medical Oncology, Mayo Clinic, discusses challenges in the treatment of patients with small cell lung cancer.

Aaron S. Mansfield, MD, discusses recent progress in small cell lung cancer and remaining challenges in the field.

Amit Mahipal, MBBS, senior associate consultant, Division of Medical Oncology, Department of Oncology, associate professor of oncology, Mayo Clinic, discusses maintenance therapy in colorectal cancer (CRC).

Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology, senior associate consultant, Division of Hematology/Oncology, Mayo Clinic, discusses the role of liquid biopsies in the treatment of patients with colorectal cancer.

Amit Mahipal, MBBS, professor of medicine, Mayo Clinic, discusses the treatment of patients with newly diagnosed metastatic colorectal cancer.

Amit Mahipal, MBBS, discusses navigating the complex treatment paradigm of metastatic colorectal cancer and sheds light on how recent advances are impacting the outlook of those affected by the disease.

Napabucasin, a novel therapy that targets cancer stem cell pathways, is being investigated in a phase III clinical trial that is believed to be the largest study ever conducted in pancreatic ductal adenocarcinoma in the metastatic setting

Ciara O'Sullivan, MB, BCh, senior associate consultant, assistant professor of oncology, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses how HER2-targeted treatment can be more individualized in the treatment of patients with HER2-positive breast cancer.

Pancreatic cancer is one of the few cancers that is on the rise, and this means that the overall cost of treating this disease is also climbing.

Matthew P. Goetz, MD, chair of the Breast Cancer Disease-Oriented Group and co-leader of the Women’s Cancer Center at the Mayo Clinic, discusses the treatment landscape for patients with metastatic hormone receptor–positive breast cancer.

Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses the role of immunotherapy in the treatment of patients with metastatic colorectal cancer.

Kabir Mody, assistant professor of medicine, consultant, Division of Hematology/Oncology, Mayo Clinic, highlights the recent treatment advances for patients with hepatocellular carcinoma.

Pashtoon M. Kasi, MD, MBBS, MS, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at Mayo Clinic, discusses the application of pharmacogenomics in colorectal cancer (CRC).

Talal Hilal, MB, BCh, assistant professor of Medicine at Mayo Clinic, discusses the benefit of maintenance rituximab (Rituxan) in the treatment of patients with mantle cell lymphoma (MCL).

Pashtoon M. Kasi, MD, MBBS, MS, an assistant professor of Oncology and senior associate consultant in the Division of Hematology/Oncology, Mayo Clinic, discusses the rising incidence of colorectal cancer (CRC).

Tanios Bekaii-Saab, MD, discusses ways to further develop precision medicine within the treatment of patients with gastrointestinal cancers.

Matthew P. Goetz, MD, chair of the Breast Cancer Disease-Oriented Group and co-leader of the Women’s Cancer Center at the Mayo Clinic, discusses survival data with CDK4/6 inhibitors in patients with hormone receptor-positive breast cancer.

Investigators are taking a personalized approach to treating patients with multiple myeloma by introducing novel agents in combination with backbone chemotherapies, based on patients’ individual genetic profiles.

Matthew P. Goetz, MD, discusses the impact of CDK4/6 inhibitors and their future role in the treatment of hormone receptor–positive breast cancer.

Pashtoon M. Kasi, MD, MBBS, MS, an assistant professor of Oncology and senior associate consultant in the Division of Hematology/Oncology, Mayo Clinic, discusses treatment approaches for patients with metastatic colorectal cancer.

Study results demonstrate that men and women differ in their immunological responses to foreign and self-antigens.

Kimberly S. Corbin, MD, radiation oncologist at the Mayo Clinic, discusses patient selection for proton therapy in breast cancer.

Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses emerging therapies for the treatment of patients with triple-negative breast cancer (TNBC).

Pashtoon M. Kasi, MD, MBBS, MS, discusses advances and unmet needs in metastatic colorectal cancer.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses resistance to targeted therapy in the treatment of patients with colorectal cancer.